JERSEY CITY, N.J.--(BUSINESS WIRE)--Exalenz Bioscience’s (TASE: EXEN) Board of Directors has approved pursuing the development of liver diagnostics in four medical indications: Clinically Significant Portal Hypertension (CSPH), Nonalcoholic Steatohepatitis (NASH), Hepatocellular Carcinoma (HCC), and Acute Liver Failure (ALF).
Help employers find you! Check out all the jobs and post your resume.
